All Pharma articles – Page 18
-
NewsExclusive: NHS England attempts to halt judicial review in drug funding row
NHS England faces threat of judicial review over refusal to fund treatment for teenager DH and NHS England are funding Xyrem for hundreds of other narcolepsy patients Lawyers argue the decision is unlawful and discriminatory NHS England has asked doctors to resubmit a bid for funding to treat ...
-
NewsExclusive: NHS England faces judicial review over narcolepsy drug refusal
NHS England has until tomorrow to decide whether to fund narcolepsy treatment for teenager 194 patients have already received NHS funding for Xyrem Lawyers claim the refusal to fund the drug is discriminatory and unlawful NHS England has until tomorrow to decide whether to fund for a teenager ...
-
SupplementsHSJ roundtable: the need to get better at sharing data
There are still shortcomings in the way the NHS shares patient information. HSJ’s latest roundtable came up with some answers
-
-
-
-
CommentThe biggest barrier to stopping HIV transmission is access to drugs
For those at greatest risk
-
-
SupplementsSupplement: Think on your feet for the best diabetes care
Give medicines optimisation a chance
-
SupplementsExcellent care supplement: Taking NHS standards to the next level
Effective management and evidence based care
-
-
SupplementsValue in Healthcare Awards 2015
Learn about this year’s winning projects in HSJ’s celebration of organisations delivering real value
-
NewsRevealed: Winners of the Value in Healthcare Awards 2015
Chosen from a record breaking number of entries
-
Supplements
Value and Healthcare Awards: Value and Improvement in Clinical Support Services
Value in Healthcare Awards winners for 2015
-
Supplements
Value in Healthcare Awards: Value and Improvement in Medicines Management
Value in Healthcare Awards winners for 2015
-
Supplements
Value in Healthcare Awards: Workforce Efficiency
Value in Healthcare Awards winners for 2015
-
CommentCuts in cancer spending expose a funding challenge
There will be tough choices over cash and cancer
-
NewsHigh profile treatments cut from cancer drugs fund
High profile cancer treatments including Roche’s Kadcyla and Avastin are to be removed from the cancer drugs fund.
-
CommentKelsey: Urgent action on a digital NHS is a moral imperative
The online revolution hasn’t reached the NHS
-
CommentDrugs access: Why the NHS is failing those with rare conditions
Access to treatment decision making